Thrombocytopenia in patients with systemic lupus erythematosus: Significant in the clinical implication and prognosis

Platelets

Volumn 21, Issue 5, 2010, Pages 380-385

  Zhao, Haifeng ^a,b   Li, Shangzhu ^a   Yang, Renchi ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b Zhejiang Xiaoshan Hospital   (China)

Author keywords

Clinical implication; Prognosis; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HEMATOLOGY; HUMAN; IMMUNE STATUS; IMMUNOLOGY; KIDNEY DISEASE; LABORATORY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOGRAPHY; NEUTROPENIA; ORGAN INJURY; PRIORITY JOURNAL; PROGNOSIS; RASH; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BLOOD; CASE CONTROL STUDY; COMPLICATION; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 77954766887     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537101003735564     Document Type: Article

References (41)

1. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 2004;13:290-297.
2. Gladman DD, Urowitz MB, Tozman EC, Glynn MF. Haemostatic abnormalities in systemic lupus erythematosus. Q J Med 1983;52:424-433.
3. Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: Association with anticardiolipin antibody. Br J Haematol 1985;59:227-230.
4. Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993;78:313-318.
5. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A, Kontopoulou- Griva I, Galeazzi M, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999;78:167-175.
6. Tolusso B, Fabris M, Gremese E, Mosca M, Rovere-Querini P, Ferraccioli GF. Platelet GPIIb/IIIa (P1A 1/2) polymorphism in SLE: clinical and laboratory association. Ann Rheum Dis 2003;62:781-782.
7. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 2000;39:399-406.
8. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980: A survey of 570 patients. Semin Arthritis Rheum 1991;21:55-64.
9. Drenkard C, Villa AR, Alarcón-Segovia D, Pérez- Vázquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994;21:1067-1072.
10. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus. Arthritis Rheum 1990;33:37-48.
11. Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995;99: 624-628.
12. Massardo L, Martinez ME, Jacobelli S, Villarroel L, Rosenberg H, Rivero S. Survival of Chilean patients with systemic lupus erythematosus. Sem Arthritis Rheum 1994;24:1-11.
13. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Int Med 1996;156:1337-1344.
14. Scofield RH, Bruner GR, Kelly JA, Kilpatrick J, Bacino D, Nath SK, Harley JB. Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13. Blood 2003;101:992-997.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640.
17. Nossent JC. Course and prognostic value of systemic lupus erythematosus disease activity index in black Caribbean patients. Semin Arthritis Rheum 1993;23:16-21.
18. Thumboo J, Lee HY, Fong KY, Chan SP, Chapman CA, Leong KH, Feng PH, Thio ST, Boey ML. Accuracy of medical record scoring of the SLICC/ACR damage index for systemic lupus erythematosus. Lupus 2000;9:358-362.
19. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: Diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976;55: 323-339.
20. Alger M, Alarcon-Segovia D, Rivero SJ. Hemolytic anemia and thrombocytopenic purpura: Two related subsets of systemic lupus erythematosus. J Rheumatol 1977;4:351-357.
21. Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum 1983;26:1181-1186.
22. Swaak AJ, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L, Smeenk RJ. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:447-454.
23. Kaplan C, Champeix P, Blanchard D, Muller JY, Cartron JP. Platelet antibodies in systemic lupus erythematosus. Br J Haematol 1987;67:89-93.
24. Pujol M, Ribera A, Vilardell M, Ordi J, Feliu E. High prevalence of platelet autoantibodies in patients with systemic lupus erythematosus. Br J Haematol 1995;89:137-141.
25. Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, Nurden AT. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: Their relationship with the observed thrombocytopenia. Br J Haematol 1997; 98:336-341.
26. Budman DR, Steinberg AD. Hematologic aspects of systemic lupus erythematosus. Current concepts. Ann Intern Med 1977;86:220-229.
27. Lurie DP, Kahaleh MB. Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus. J Rheumatol 1982;9:311-314.
28. Ishikawa A, Okada J, Kondo H. Anti-platelet antibodies in sera from patients with systemic lupus erythematosus by immunoblot analysis. Nihon Rinsho Meneki Gakkai Kaishi 1995;18:20-28.
29. Hakim AJ, Machin SJ, Isenberg DA. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: The response to splenectomy. Semin Arthritis Rheum 1998;28:20-25.
30. Lavalle C, Hurtado R, Quezada JJ, Cabral A, Fraga A. Hemocytopenia as initial manifestation of systemic lupus erythematosus: Prognostic significance. Clin Rheumatol 1983;2:227-232.
31. Mestanza-Peralta M, Ariza-Ariza R, Cardiel MH, Alcocer- Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997;24: 867-870.
32. Bruyn GA. Controversies in lupus: Nervous system involvement. Ann Rheum Dis 1995;54:159-167.
33. Futrell N, Schultz LR, Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology 1992;42:1649-1657.
34. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, Roubey RA, Dooley MA. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161-167.
35. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med 2000;108:198-204.
36. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006;85:147-156. (Pubitemid 43833013)
37. Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: Clinical implications and prognostic significance. Ann Rheum Dis 2005;64:1366-1369.
38. Chang HK. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J Korean Med Sci 2005;20: 883-885.
39. Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol 2006;133:53-55.
40. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 2004;40:286-292.
41. Balsalobre Aznar J, Herráez Herrera P, Porta Etessam J, Torres Mart́n C, Bermell Serrano JC, Núnez López R, Mateo Bernardo I, Padrino Mart́nez JM, Morillas López L. Idiopathic thrombocytopenic purpura as first manifestation of systemic lupus erythematosus lupus. An Med Interna 1999;16:611-614.